Big Pharma Stock Pfizer Downgraded, Could Mark Bottom
Goldman analyst James Kelly cut his rating from “buy” to “neutral” and price target from $26 to $22 for Pfizer Inc. (PFE)...

Continue Reading Big Pharma Stock Pfizer Downgraded, Could Mark Bottom

Stat of the Day: Pfizer at $19, Lowest Level Since 1997
Pfizer Inc. (PFE) hit its lowest level since 1997 and has fallen eight out of the past nine trading sessions since May 19 to nearly crack $19...

Continue Reading Stat of the Day: Pfizer at $19, Lowest Level Since 1997


Pfizer: The Ever-Devaluing Big Pharma Value Stock
Pfizer Inc. (PFE) Chief Executive Jeffrey Kindler said this morning at the drug maker’s annual shareholder meeting that his plan is t...

Continue Reading Pfizer: The Ever-Devaluing Big Pharma Value Stock

Why I (Largely) Ignore the Dow Jones Industrial Average
[begin soapbox] All the hype talk about the Dow being close to a new high has been driving me nuts. It always annoys me when people refer to...

Continue Reading Why I (Largely) Ignore the Dow Jones Industrial Average